Trial · NCT06548204
Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
NCT06548204, Phase 2, Recruiting, Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial. Trials, record NCT06548204. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06548204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
- NCT number
- NCT06548204
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI)
- Interventions
- Fexofenadine Hydrochloride, Placebo
- First posted
- 2024-08-12
- Last updated
- 2026-09-16
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Late gadolinium enhancement/Left ventricular mass (LGE/LV%) | 6 months after myocardial infarction | The difference of LGE/LV% from baseline. LGE/LV% will be assessed by CMR. |
| Secondary | Left ventricular ejection fraction (LVEF) | 6 months after myocardial infarction | The difference of LVEF from baseline. LVEF will be assessed by CMR. |
| Secondary | Left ventricular end-systolic volume/body surface area (LVESV/BSA%) | 6 months after myocardial infarction | The difference of LVESV/BSA% from baseline. LVESV will be assessed by CMR and BSA will be calculated by height and weight. |
| Secondary | Left ventricular end-diastolic volume/body surface area (LVEDV/BSA%) | 6 months after myocardial infarction | The difference of LVEDV/BSA% from baseline. LVEDV will be assessed by CMR and BSA will be calculated by height and weight. |
| Secondary | Left ventricular ejection fraction (LVEF) | 6 months after myocardial infarction | The difference of LVEF from baseline. LVEF will be assessed by UCG. |
| Secondary | Left ventricular end-systolic volume/body surface area (LVESV/BSA%) | 6 months after myocardial infarction | The difference of LVESV/BSA% from baseline. LVESV will be assessed by UCG and BSA will be calculated by height and weight. |
| Secondary | Left ventricular end-diastolic volume/body surface area (LVEDV/BSA%) | 6 months after myocardial infarction | The difference of LVEDV/BSA% from baseline. LVEDV will be assessed by UCG and BSA will be calculated by height and weight. |
| Secondary | Extracellular volume (ECV) | 6 months after myocardial infarction | The difference of ECV from baseline. ECV will be assessed by CMR. |
| Secondary | Intramyocardial hemorrhage (IMH) | 6 months after myocardial infarction | Analysis of differences of IMH from baseline. |
| Secondary | stroke volume | 6 months after myocardial infarction | Analysis of differences of stroke volume from baseline. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06548204
GET https://conductscience.org/api/trials/v1/NCT06548204/registered